134 related articles for article (PubMed ID: 38881902)
1. From mechanism to therapy: the journey of CD24 in cancer.
Zhao K; Wu C; Li X; Niu M; Wu D; Cui X; Zhao H
Front Immunol; 2024; 15():1401528. PubMed ID: 38881902
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD24 as a novel immunotherapy for solid cancers.
Yang Y; Zhu G; Yang L; Yang Y
Cell Commun Signal; 2023 Nov; 21(1):312. PubMed ID: 37919766
[TBL] [Abstract][Full Text] [Related]
3. Involvement of CD24 in Multiple Cancer Related Pathways Makes It an Interesting New Target for Cancer Therapy.
Eyvazi S; Kazemi B; Dastmalchi S; Bandehpour M
Curr Cancer Drug Targets; 2018; 18(4):328-336. PubMed ID: 28820056
[TBL] [Abstract][Full Text] [Related]
4. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy.
Barkal AA; Brewer RE; Markovic M; Kowarsky M; Barkal SA; Zaro BW; Krishnan V; Hatakeyama J; Dorigo O; Barkal LJ; Weissman IL
Nature; 2019 Aug; 572(7769):392-396. PubMed ID: 31367043
[TBL] [Abstract][Full Text] [Related]
5. Novel insights into the function of CD24: A driving force in cancer.
Altevogt P; Sammar M; Hüser L; Kristiansen G
Int J Cancer; 2021 Feb; 148(3):546-559. PubMed ID: 32790899
[TBL] [Abstract][Full Text] [Related]
6. The CD24 protein inducible expression system is an ideal tool to explore the potential of CD24 as an oncogene and a target for immunotherapy in vitro and in vivo.
Shapira S; Kazanov D; Weisblatt S; Starr A; Arber N; Kraus S
J Biol Chem; 2011 Nov; 286(47):40548-55. PubMed ID: 21976680
[TBL] [Abstract][Full Text] [Related]
7. CD24 controls Src/STAT3 activity in human tumors.
Bretz NP; Salnikov AV; Perne C; Keller S; Wang X; Mierke CT; Fogel M; Erbe-Hofmann N; Schlange T; Moldenhauer G; Altevogt P
Cell Mol Life Sci; 2012 Nov; 69(22):3863-79. PubMed ID: 22760497
[TBL] [Abstract][Full Text] [Related]
8. Contractile forces contribute to increased glycosylphosphatidylinositol-anchored receptor CD24-facilitated cancer cell invasion.
Mierke CT; Bretz N; Altevogt P
J Biol Chem; 2011 Oct; 286(40):34858-71. PubMed ID: 21828044
[TBL] [Abstract][Full Text] [Related]
9. NDRG2 inhibits hepatocellular carcinoma adhesion, migration and invasion by regulating CD24 expression.
Zheng J; Li Y; Yang J; Liu Q; Shi M; Zhang R; Shi H; Ren Q; Ma J; Guo H; Tao Y; Xue Y; Jiang N; Yao L; Liu W
BMC Cancer; 2011 Jun; 11():251:1-9. PubMed ID: 21676268
[TBL] [Abstract][Full Text] [Related]
10. CD24 interacts with and promotes the activity of c-src within lipid rafts in breast cancer cells, thereby increasing integrin-dependent adhesion.
Baumann P; Thiele W; Cremers N; Muppala S; Krachulec J; Diefenbacher M; Kassel O; Mudduluru G; Allgayer H; Frame M; Sleeman JP
Cell Mol Life Sci; 2012 Feb; 69(3):435-48. PubMed ID: 21710320
[TBL] [Abstract][Full Text] [Related]
11. CD24 blockade as a novel strategy for cancer treatment.
Wang Y; Yu H; Yu M; Liu H; Zhang B; Wang Y; Zhao S; Xia Q
Int Immunopharmacol; 2023 Aug; 121():110557. PubMed ID: 37379708
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions.
Li X; Tian W; Jiang Z; Song Y; Leng X; Yu J
Cancer Immunol Immunother; 2024 Jan; 73(2):31. PubMed ID: 38279998
[TBL] [Abstract][Full Text] [Related]
13. LncRNA IL21-AS1 facilitates tumour progression by enhancing CD24-induced phagocytosis inhibition and tumorigenesis in ovarian cancer.
Liu J; Yan C; Xu S
Cell Death Dis; 2024 May; 15(5):313. PubMed ID: 38702326
[TBL] [Abstract][Full Text] [Related]
14. Targeting the GPI transamidase subunit GPAA1 abrogates the CD24 immune checkpoint in ovarian cancer.
Mishra AK; Ye T; Banday S; Thakare RP; Su CT; Pham NNH; Ali A; Kulshreshtha A; Chowdhury SR; Simone TM; Hu K; Zhu LJ; Eisenhaber B; Deibler SK; Simin K; Thompson PR; Kelliher MA; Eisenhaber F; Malonia SK; Green MR
Cell Rep; 2024 Apr; 43(4):114041. PubMed ID: 38573857
[TBL] [Abstract][Full Text] [Related]
15. CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion.
Bretz N; Noske A; Keller S; Erbe-Hofmann N; Schlange T; Salnikov AV; Moldenhauer G; Kristiansen G; Altevogt P
Clin Exp Metastasis; 2012 Jan; 29(1):27-38. PubMed ID: 21984372
[TBL] [Abstract][Full Text] [Related]
16. CD24 cell surface expression in Mvt1 mammary cancer cells serves as a biomarker for sensitivity to anti-IGF1R therapy.
Rostoker R; Ben-Shmuel S; Rashed R; Shen Orr Z; LeRoith D
Breast Cancer Res; 2016 May; 18(1):51. PubMed ID: 27179633
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-mediated CD24 expression is correlated with gastric cancer aggressiveness by promoting cell migration and invasion.
Fujikuni N; Yamamoto H; Tanabe K; Naito Y; Sakamoto N; Tanaka Y; Yanagihara K; Oue N; Yasui W; Ohdan H
Cancer Sci; 2014 Nov; 105(11):1411-20. PubMed ID: 25174257
[TBL] [Abstract][Full Text] [Related]
18. CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y; Harutani Y; Oyanagi J; Akamatsu H; Murakami E; Shibaki R; Hayata A; Sugimoto T; Tanaka M; Takakura T; Furuta K; Okuda Y; Sato K; Teraoka S; Ueda H; Tokudome N; Kitamura Y; Fukuoka J; Nakanishi M; Koh Y; Yamamoto N
Cancer Sci; 2021 Jan; 112(1):72-80. PubMed ID: 33084148
[TBL] [Abstract][Full Text] [Related]
19. The CD24 surface antigen in neural development and disease.
Gilliam DT; Menon V; Bretz NP; Pruszak J
Neurobiol Dis; 2017 Mar; 99():133-144. PubMed ID: 27993646
[TBL] [Abstract][Full Text] [Related]
20. Checkpoint CD24 function on tumor and immunotherapy.
Huang S; Zhang X; Wei Y; Xiao Y
Front Immunol; 2024; 15():1367959. PubMed ID: 38487533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
